Graviti Pharms Company Profile
What is the competitive landscape for GRAVITI PHARMS
GRAVITI PHARMS has seventeen approved drugs.
Drugs and US Patents for Graviti Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Graviti Pharms | HYDROXYZINE HYDROCHLORIDE | hydroxyzine hydrochloride | TABLET;ORAL | 217652-003 | Aug 17, 2023 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Graviti Pharms | FUROSEMIDE | furosemide | TABLET;ORAL | 216629-001 | Oct 17, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Graviti Pharms | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 211020-002 | Jan 28, 2019 | AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Graviti Pharms | ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 078777-003 | Sep 11, 2012 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Graviti Pharms | LORAZEPAM | lorazepam | TABLET;ORAL | 218597-003 | Jul 24, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Graviti Pharms | FUROSEMIDE | furosemide | TABLET;ORAL | 216629-003 | Oct 17, 2022 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

